Braveheart Bio (NASDAQ:BRVE) Shares Gap Up – Should You Buy?

Braveheart Bio, Inc. (NASDAQ:BRVE)’s stock price gapped up before the market opened on Monday. The stock had previously closed at $17.42, but opened at $19.08. Braveheart Bio shares last traded at $18.96, with a volume of 3,487 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BRVE. Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. The Goldman Sachs Group began coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 price target on the stock. Weiss Ratings started coverage on shares of Braveheart Bio in a report on Monday, November 2nd. They set a “sell (d-)” rating for the company. Jefferies Financial Group initiated coverage on Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 price objective for the company. Finally, TD Cowen initiated coverage on Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating on the stock. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Braveheart Bio Stock Performance

The company has a 50 day simple moving average of $22.44.

Braveheart Bio (NASDAQ:BRVE) last announced its earnings results on Tuesday, November 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.40. Analysts anticipate that Braveheart Bio, Inc. will post -1.99 EPS for the current year.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.